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DObjective: The benefits and risks associated with the use of clopidogrel before coronary artery bypass grafting
are controversial, and these were investigated in the present meta-analysis.
Methods: A systematic literature search was performed to identify studies on the use of clopidogrel before cor-
onary artery bypass grafting. Meta-analysis was performed according to the Cochrane Handbook for Systematic
Reviews.
Results: The literature search yielded 3 prospective randomized studies and 17 observational studies with valid
data. Randomized studies were post hoc analyses of the Clopidogrel as Adjunctive Reperfusion Therapy
(CLARITY), Clopidogrel for the Reduction of Events During Observation (CREDO), and Clopidogrel in
Unstable Angina to Prevent Recurrent Ischemic Events trials. Meta-analysis based on these data showed a non-
significant reduced risk of immediate postoperative composite end point (death, myocardial infarction, or
stroke) in the clopidogrel group (risk ratio [RR], 0.77; 95% confidence interval [CI], 0.58–1.04). Data from
the CREDO and CLARITY trials showed a similar risk of death (RR, 0.81; 95% CI, 0.20–3.37), myocardial
infarction (RR, 0.58; 95% CI, 0.25–1.33), and major bleeding according to Thrombolysis in Myocardial Infarc-
tion criteria (RR, 1.48; 95% CI, 0.72–3.04). Meta-analysis of observational studies showed that preoperative
exposure to clopidogrel was associated with an increased risk of death (RR, 1.30; 95% CI, 1.02–1.67), reopera-
tion for bleeding (RR, 1.88; 95% CI, 1.37–2.58), blood loss (mean difference, 157.8 mL; 95% CI, 61.9–253.6),
need of packed red blood cell transfusion (RR, 1.23; 95%CI, 1.10–1.37), and increased use of blood products. A
significantly reduced risk of postoperative myocardial infarction was observed among patients taking clopidog-
rel (RR, 0.63; 95% CI, 0.48–0.82).
Conclusions: Contrary to the findings of post hoc analyses of randomized trials, observational studies showed
that recent exposure to clopidogrel before coronary artery bypass grafting is associated with increased risk of
postoperative death, reoperations for bleeding, blood loss, and need of blood transfusions. (J Thorac Cardiovasc
Surg 2012;143:665-75)Supplemental material is available online.
Current guidelines for the management of acute coronary
syndrome recommend upstream use of dual antiplatelet
therapy with clopidogrel and aspirin before diagnostic cor-
onary angiography.1,2 Upstream loading with clopidogrel
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The Journal of Thoracic and Cainterventions3 and is commonly used in clinical practice.
Despite the proven benefits of dual antiplatelet treatment
in these settings, cardiac surgeons frequently face a possible
increased risk of bleeding and resternotomy in patients un-
dergoing coronary artery bypass grafting (CABG) early af-
ter diagnostic coronary angiography or failed percutaneous
coronary intervention. Although it may be advisable to
withhold clopidogrel administration in patients who are
likely to require CABG, there are no reliable predictors
for the need of CABG before diagnostic coronary
angiography.4
After a decade of widespread use of clopidogrel before
urgent/emergency CABG, the potential benefits and risks
associated with preoperative dual antiplatelet regimen in
surgical patients are still controversial. We hypothesized
that the trends toward reduced cardiovascular complica-
tions in limited data from post hoc analyses of clinical trials
may not be evident in clinical practice. We performed the
present systematic review and meta-analysis to address
this hypothesis.rdiovascular Surgery c Volume 143, Number 3 665
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CLARITY ¼ Clopidogrel as Adjunctive
Reperfusion Therapy
CREDO ¼ Clopidogrel for the Reduction of
Events During Observation
CURE ¼ Clopidogrel in Unstable Angina to
Prevent Recurrent Ischemic Events
RR ¼ risk ratio
TIMI ¼ Thrombolysis in Myocardial
Infarction
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DMATERIALS AND METHODS
This meta-analysis was performed in accordance with the Cochrane
Handbook for Systematic Reviews.5 Reference search was performed
through PubMed, Cochrane Library, and Scopus up to July 1, 2010, for
studies evaluating the combination of clopidogrel and aspirin versus aspirin
alone in patients undergoing CABG. The words used in the search were
clopidogrel, coronary artery bypass surgery, coronary artery bypass graft-
ing, surgical, and revascularization.
Studies in which none of the control patients received aspirin were ex-
cluded from this analysis. Moreover, we excluded those studies in which
most of the control patients had been exposed to clopidogrel even if the
drug was discontinued 5 to 7 days before surgery, because the latter may
introduce a bias in terms of indication for urgent surgery6,7 and affect the
outcome end points. We also excluded those studies reporting use of
aprotinin in more than 10% of patients because this drug may reduce
hemorrhagic complications in these patients and significantly increase
the mortality risk.8 Studies including patients undergoing procedures other
than isolated CABG were excluded from this analysis.
Prospective, randomized studies of patients undergoing isolated CABG
with allocation to preoperative use of clopidogrel or placebo in addition to
aspirin were included at first in this analysis. In the present analysis, we in-
cluded only patients who underwent CABG during the initial hospitaliza-
tion because delayed surgery may introduce a bias of late exposure and
discontinuation to clopidogrel. Clinical variables and outcome end points
were reported as originally defined by the authors. For the second step,
we performed a meta-analysis of observational studies on this topic.
No extramural funding was used to support this work. The authors are
solely responsible for the design and conduct of this study, all study anal-
yses, the drafting and editing of the article, and its final contents.Data Collection and Assessment of Data Quality
Two authors (F.B., K.E.J.A.) independently abstracted data from all el-
igible studies using an Excel file (Microsoft Corp, Redmond, Wash). We
retrieved data on study design, study size, patient demographics, and any
major outcome end points. Data were retrieved from the articles, and an at-
tempt was made to retrieve missing data only from the authors of prospec-
tive, randomized studies.
The risk of bias possibly affecting prospective, randomized studies has
been assessed independently by the authors (F.B., K.E.J.A.) and reviewed
by one author (F.B.) according to the Cochrane Collaboration criteria for
assessing risk of bias.5 Disagreement has been resolved by consensus.
Trials that met eligibility criteria have been assessed for generation of ran-
dom allocation sequence, allocation concealment, blinding of intervention,
incomplete outcome data, freedom of selective reporting, and freedom of
other biases. These parameters were categorized as yes, unclear, or no.666 The Journal of Thoracic and Cardiovascular SurgThe quality of observational, cohort studies was assessed with the New-
castle–Ottawa Scale, which is a 9-point scale that assigns points on the ba-
sis of the process of selection (0–4 points), comparability (0–2 points), and
identification of the outcomes of study participants (0–3 points) in cohort
studies.9
Outcomes of Interest
The outcome end points evaluated in this analysis were cardiovascular
death, myocardial infarction, stroke, or a combination of the latter adverse
events; major bleeding as defined by Thrombolysis in Myocardial Infarc-
tion (TIMI) criteria10; need of reoperation for bleeding; postoperative
blood loss; need of packed red blood cells transfusion; and the amount
of units of packed red blood cells, fresh-frozen plasma, and platelets trans-
fused. Renal failure was not considered as an outcome of interest because
the definition of this end point may vary markedly.
Statistical Analysis
Meta-analysis was performed using Review Manager 5.0.18 (Copenha-
gen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008).
Risk of adverse event is expressed as risk ratio (RR) with 95% confidence
interval (CI). Continuous variables were reported as weighted mean differ-
ences and 95% CI. Heterogeneity was assessed by using the I2 statistic. I2
less than 40% has been considered as an unimportant heterogeneity. In case
of important heterogeneity, we have used the random-effects model.
Analyses were initially performed separately for randomized trials and
observational studies because of the distinct nature of these studies. A
pooled analysis of all studies was then performed. We did not perform
meta-regression analysis because of the small number of studies included.RESULTS
Search Results of Prospective, Randomized Studies
The literature search of prospective, randomized studies
initially yielded 21 articles that were pertinent to this issue
and potentially being prospective and randomized trials.
The literature search flowchart is shown in Figure 1. A
search in Clinicaltrials.gov yielded no studies dealing
with preoperative use of clopidogrel plus aspirin versus as-
pirin alone before CABG surgery.
Overall, only 3 prospective, randomized studies11-13
were available for data retrieval and meta-analysis. The rea-
sons for excluding the other studies are reported in detail in
Table E1. The included studies were post hoc analyses of 3
large prospective randomized trials11-13; thus, allocation
into the revascularization subgroups was not randomized,
and a potential bias may exist. However, clopidogrel was
administered in a randomized and blinded fashion, and
any bias at allocation may be balanced between the
clopidogrel and control groups. These post hoc analyses
included 3.9%11,12 to 8.1%13 of the initially enrolled pa-
tients. Characteristics of these studies are summarized in
Table 1. Risk of bias of these trials is reported in Table 2.Description of Prospective, Randomized Studies
Clopidogrel as Adjunctive Reperfusion Therapy–TIMI
28 trial. The Clopidogrel as Adjunctive Reperfusion
Therapy (CLARITY)–TIMI 28 trial was carried out at
319 sites in 23 countries between 2003 and 2004.14 The trialery c March 2012
Potentially relevant trials identified and 
screened for retrieval             
n=21
RCTs retrieved for more detailed 
evaluation                                    
n=8
Appropriate RCTs to be included in the 
meta-analysis             
n=3
Non-random design 
n=13
RCTs without appropriate 
control group 
n=5
FIGURE 1. Literature search and study selection of randomized con-
trolled trials. RCT, Randomized controlled trial.
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Denrolled 3491 patients with ST-elevation myocardial infarc-
tion who were scheduled to receive a fibrinolytic agent, an
anticoagulant (if a fibrin-specific lytic agent was pre-
scribed), and aspirin. Patients were randomly assigned to re-
ceive either clopidogrel (300-mg loading dose followed by
75mg/d) or placebo in a double-blind fashion. Patients were
to receive study medication daily up to and including the
day of coronary angiography. For patients who did not un-
dergo angiography, the study drug was to be administered
up to and including day 8 or hospital discharge, whichever
came first. All patients were to be treated with a fibrinolytic
agent, aspirin 150 to 325 mg on the first day and 75 to 162
mg/d thereafter, and for those receiving a fibrin-specific
lytic agent, heparin for 48 hours. CLARITY trialists re-
ported the results of a post hoc analysis of 136 patients
(66 in the clopidogrel group and 70 in the control group)
who underwent CABG a median of 8 days after randomiza-
tion and 4 days from coronary angiography.12 Study medi-
cation was interrupted a median of 5 days before CABG.
Clopidogrel for the Reduction of Events During Obser-
vation trial. The Clopidogrel for the Reduction of Events
During Observation (CREDO)3 trial was a randomized,
double-blind, placebo-controlled trial conducted among
2116 patients who were to undergo elective percutaneous
coronary intervention or deemed at high likelihood of under-
going percutaneous coronary intervention, enrolled at 99
centers in North America from 1999 to 2001. Patients
were randomly assigned to receive clopidogrel 300 mg
(n ¼ 1053) or placebo (n ¼ 1063) 3 to 24 hours before per-
cutaneous coronary intervention. Thereafter, all patients re-
ceived clopidogrel, 75mg/d, through day 28. From day 29 to
12 months, patients in the loading-dose group received clo-
pidogrel, 75 mg/d, and those in the control group received
placebo. Both groups received aspirin throughout the study.The Journal of Thoracic and CaForty-one patients in the clopidogrel group and 42 patients
in the control group underwent CABG during the same hos-
pitalization and were included in a post hoc analysis.13
Clopidogrel in Unstable Angina to Prevent Recurrent
Ischemic Events trial. The Clopidogrel in Unstable An-
gina to Prevent Recurrent Ischemic Events (CURE) trial
was a randomized, double-blind, placebo-controlled trial
comparing clopidogrel with placebo in 12,562 patients pre-
senting with non–ST-elevation myocardial infarction.15 Pa-
tients were recruited from December 1998 to September
2000 at 428 centers in 28 countries. All patients received as-
pirin 75 mg to 325 mg. Patients were randomly assigned to
clopidogrel (loading dose of 300 mg orally and then 75 mg
daily) or matching placebo on a double-blind basis and con-
tinued for 3 to 12 months.
Of the 12,562 randomized patients, 2072 (16.5%) under-
went CABG and were the subjects of a post hoc analysis.11
A total of 1015 patients (530 placebo- and 485 clopidogrel-
treated patients) underwent surgical revascularization dur-
ing the initial hospitalization after a median of 12 to 13
days and are included in the present analysis. For patients
proceeding to CABG, the timing of discontinuation of clo-
pidogrel and aspirin was at the discretion of the surgeon and
local treatment policy. The other patients were excluded
from the analysis because of the long median period from
randomization to surgery (67.5–73.0 days) and because
these patients discontinued the study drug for a median of
17 days before surgery.
Pooled Outcome of Prospective, Randomized Studies
We requested supplemental data from the trials’ principal
investigators, and the only data were provided from the
CREDO trialists. Data on composite end point (death, myo-
cardial infarction, or stroke) at 30 days were available from
the CREDO and CLARITY trials, whereas we extracted the
data of the CURE study from the hazard rate curve of pa-
tients who underwent surgery during index hospitalization.
The authors stated that the median time from randomization
to surgery was 12 days11; therefore, we extracted the com-
posite end point rates at 30 days since the median time to
CABG. Fixed effect analysis showed that there was a non-
significant trend toward a reduced risk of composite end
point in the clopidogrel group (RR, 0.77; 95% CI, 0.58–
1.04; I2 ¼ 0%; Figure 2).
Data from CREDO and CLARITY showed similar im-
mediate postoperative mortality (RR, 0.81; 95% CI, 0.20–
3.37; I2 ¼ 0%) and myocardial infarction (RR, 0.58; 95%
CI, 0.25–1.33; I2 ¼ 0%), but still in favor of clopidogrel-
treated patients. No postoperative stroke was observed in
both these studies. Data from the CREDO and CLARITY
trials showed a similar risk of major bleeding according
to TIMI criteria (RR, 1.48; 95% CI, 0.72–3.04; I2 ¼ 0%)
in the clopidogrel and control groups. Only the CLARITY
study reported on the rate of reoperation for bleeding, whichrdiovascular Surgery c Volume 143, Number 3 667
TABLE 1. Characteristics of randomized trials included in meta-analysis
Study Population Participants Methods
Available outcomes
of interest of the
present study Source of funding
CLARITY Ischemic discomfort at
rest within 12 h before
randomization that
lasted more than 20
min; if patients had ST-
segment elevation of at
least 0.1 mVin at least 2
contiguous limb leads,
ST-segment elevation
of at least 0.2 mV in at
least 2 contiguous
precordial leads, or left
bundle-branch block
that was not known to
be old; and if they were
scheduled to receive
a fibrinolytic agent, an
anticoagulant (if
a fibrin-specific lytic
agent was prescribed),
and aspirin.
136 patients who
underwent CABG
This trial enrolled initially
3491 patients.
Prospective, randomized
double-blind, placebo
controlled, multicenter
trial. Post hoc analysis
A total of 66 patients
received clopidogrel
300-mg loading dose
followed by 75 mg/
d before CABG.
A total of 70 patients
received placebo before
CABG.
All patients received
a fibrinolytic agent,
aspirin 150–325 mg on
the first day and 75–162
mg daily thereafter, and
for those receiving
a fibrin-specific lytic
agent, heparin for 48 h.
30-d cardiovascular death,
myocardial infarction,
stroke, TIMI, major
bleeding, and
composite end point
(cardiovascular death,
myocardial infarction,
or stroke)*
Supported in part by
Sanofi-Synthelabo
(Paris, France)/
Bristol-Myers Squibb
(New York, NY)
CREDO Patients with symptomatic
coronary artery disease
with objective evidence
of ischemia referred for
or thought to be at high
likelihood for requiring
percutaneous coronary
intervention.
83 patients who
underwent CABG
without index
percutaneous coronary
intervention
This trial enrolled initially
2116 patients.
Prospective, randomized
double-blind, placebo
controlled, multicenter
trial; post hoc analysis
A total of 41 patients
received clopidogrel
300 mg and aspirin 325
mg before planned
percutaneous coronary
intervention.
A total of 42 control
patients received
placebo and aspirin 325
mg before planned
percutaneous coronary
intervention.
All patients received both
clopidogrel 75 mg/d
and aspirin 325 mg/d
until day 28 after
percutaneous coronary
intervention (treatment
of patients undergoing
CABG unknown).
28-d cardiovascular death,
myocardial infarction,
stroke, TIMI, major
bleeding, and
composite end point
(cardiovascular death,
myocardial infarction,
or stroke)
Sanofi-Synthelabo/
Bristol-Myers Squibb
(Continued)
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TABLE 1. Continued
Study Population Participants Methods
Available outcomes
of interest of the
present study Source of funding
CURE Patients with acute
coronary syndrome
within the preceding 24
h in the absence of ST-
elevation of>1 mm on
the electrocardiogram.
Other supporting evidence
of myocardial ischemia
was required in the
form of
electrocardiogram
criteria or elevated
cardiac enzymes at
least twice the upper
limit of normal.
1015 patients who
underwent CABG
during index
hospitalization
This trial initially enrolled
12,562 patients.
Prospective, randomized
double-blind, placebo-
controlled, multicenter
trial; post hoc analysis.
A total of 485 patients
received a loading dose
of clopidogrel 300 mg
followed by clopidogrel
75 mg/d plus aspirin
75–325 mg/d before
CABG during index
hospitalization.
A total of 530 patients
received placebo and
aspirin 75–325 mg/d
before CABG during
index hospitalization.
Immediate postoperative
composite end point
(cardiovascular death,
myocardial infarction,
or stroke)
Sanofi-Synthelabo/
Bristol-Myers Squibb
*This composite end point included cardiovascular death, recurrent myocardial infarction, and recurrent ischemia requiring urgent revascularization. Because no stroke occurred
in both study groups and recurrent ischemia requiring urgent revascularization was likely myocardial infarction, we have considered cardiovascular death, myocardial infarction,
or stroke as composite end point.
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Dwas 6.7% in the clopidogrel group and 14.3% in the control
group (P ¼ .43). The rate of reoperation for bleeding in
patients stopping study medication 5 days or less before
surgery was 11.4% in the clopidogrel group and 10.5%
in the control group (P ¼ 1.00).Search Results and PooledOutcome of Observational
Studies
The search of observational studies initially yielded 40
articles that were pertinent to this issue and potentially eval-
uating the impact of preoperative use of clopidogrel before
CABG. Seventeen studiesE1-E17 were found to provide valid
data for this meta-analysis. The literature search flowchart
for observational studies is shown in Figure 3.
Themain characteristics of these studies and their grading
according to the Newcastle–Ottawa Scale are summarized
in Table 3. Only 2 studies had comparable cohorts according
to the Newcastle–Ottawa Scale criteria. All studies but one
included patients exposed to clopidogrel 7 days or less be-
fore surgery, and 8 studies included patients in whom clopi-
dogrel was stopped 5 days or less before surgery.TABLE 2. Risk of bias of prospective, randomized trials included in this m
Study Sequence generation
Allocation
concealment Blinding
CLARITY Central, computerized
randomization
No Yes
CREDO Randomization in blocks of 2 No Yes
CURE Central, computerized
randomization
No Yes
The Journal of Thoracic and CaExposure to clopidogrel during the immediate preopera-
tive period was associated with an increased risk of death
(13 studies including 12,129 patients: RR, 1.30; 95% CI,
1.02–1.67; Figure 4), reoperation for bleeding (RR, 1.88;
95% CI, 1.37–2.58; Figure 5), blood loss (mean difference,
157.8 mL; 95% CI, 61.9–253.6; Figure 6), need of packed
red blood cell transfusion (RR, 1.23; 95% CI, 1.10–1.37;
Figure 7), and amount of packed red blood cells (mean dif-
ference, 0.77 units; 95% CI,0.05 to 1.59), fresh-frozen
plasma (mean difference, 0.35 units; 95% CI, 0.22–0.49),
and platelets (mean difference, 2.41 units; 95% CI,0.03
to 4.86) transfused. A significantly reduced risk of postop-
erative myocardial infarction was observed among patients
receiving clopidogrel (RR, 0.63; 95% CI, 0.48–0.82;
Figure 8), whereas this drug was not associated with any
benefit or harm in terms of postoperative stroke (RR, 1.26;
95% CI, 0.78–2.02).
Inclusion in the analysis of observational studies evaluat-
ing emergency cases resulted in a slightly, nonsignificant in-
crease of the risk of immediate postoperative death in
patients exposed preoperatively to clopidogrel (RR, 1.24;eta-analysis
Incomplete outcome data
addressed
Free of selective
reporting
Free of other
biases
No Yes No
Yes Yes No
Unclear No No
rdiovascular Surgery c Volume 143, Number 3 669
FIGURE 2. Risk of 30-day postoperative composite cardiovascular event (cardiovascular death, myocardial infarction, or stroke) in patients who received
clopidogrel versus placebo before CABG. Only data from post hoc analysis of prospective randomized trials are included in this analysis. CLARITY,
Clopidogren as Adjunctive Reperfusion Therapy; CREDO, Clopidogrel for the Reduction of Events During Observation; CURE, Clopidogrel in Unstable
Angina to Prevent Recurrent Ischemic Events; CI, confidence interval.
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D95% CI, 0.95–1.61). The risk of resternotomy for bleeding
was also increased in those studies excluding emergency
cases (RR, 3.10; 95% CI, 1.52–6.34).
When data from the CLARITYand CREDO studies were
included in the analysis of observational studies, clopidog-
rel was still associated with increased postoperative death
(RR, 1.28; 95% CI, 1.00–1.64) and reduced risk of postop-
erative myocardial infarction (RR, 0.63; 95% CI, 0.49–
0.81).
Data from 627 patients included in 2 prospective studies
(CLARITY, CREDO) and 2 observational studies fulfilling
Newcastle–Ottawa criteria of group comparability showed
a nonsignificant trend toward increased risk ofPotentially relevant observational 
studies screened for retrieval             
n=289
Studies retrieved for more detailed 
evaluation                                    
n=40
Appropriate observational studies to 
be included in this analysis 
n=17
Non-English language 
n=1
Studies not pertinent 
n=249
Studies without appropriate 
study design 
n=22
Studies evaluated for appropriateness 
of design
n=39
FIGURE 3. Literature search and study selection of observational studies.
670 The Journal of Thoracic and Cardiovascular Surgpostoperative death with the use of clopidogrel (RR, 1.51;
95% CI, 0.64–3.54).
Patients in whom clopidogrel was withheld 4 days or less
before surgery were shown to have an increased risk of
blood loss (mean difference, 87.8 mL; 95% CI, 48.0–
128.6) and a trend for increased risk of resternotomy for
bleeding (RR, 2.76; 95% CI, 0.5513.76). However, these
findings are biased by the small number of patients exposed
to clopidogrel (113 patients and 140 patients, respectively).
Among these studies, no data were available for analysis of
the other outcome end points.DISCUSSION
The results of this systematic review and meta-analysis
indicate that the current knowledge on the impact of preop-
erative use of clopidogrel on outcome after CABG is based
on only a few studies of suboptimal quality. The lack of pro-
spective randomized studies on this topic is of particular rel-
evance. Indeed, we were able to identify and include in the
present meta-analysis only post hoc analyses of 3 large pro-
spective randomized trials. Thus, allocation into the revas-
cularization subgroups was not randomized, and
a potential bias may exist. However, clopidogrel was ad-
ministered in a randomized and blinded fashion, and any
bias at allocation should be balanced between the clopidog-
rel and control groups.13 These studies included only 3.9%
to 8.1% of the initially enrolled patient populations in the
main trials.12,13 Furthermore, details on the timing of
clopidogrel discontinuation were not recorded at the time
of the original trials.
Most of the available studies on this issue are retrospec-
tive analyses, and only 7 studies (despite the inappropriate
study design of some of these) used propensity score anal-
ysis (Table E2), which may reduce the impact of confound-
ing in the estimation of causal treatment effects with
nonrandomized data. This is of particular concern in
clopidogrel-exposed patients because their characteristics
may significantly differ from those who did not receiveery c March 2012
TABLE 3. Characteristics and Newcastle–Ottawa quality assessment of observational studies on the use of clopidogrel before coronary artery bypass surgery included in this meta-analysis
Study
Study
design Control Clopidogrel
Clopidogrel
stopped before
surgery (d)
Emergency
cases
included Representativeness Selection
Ascertainment
of exposure
Outcome not
present at
start of study Comparability
Assessment
of outcome
Follow-up
long enough
Adequacy of
follow-up
Ascione and colleagues
2005E1
R 246 91 5 No + + + + + +
Chen and colleagues
2004E2
P 45 45 6 No + + + + + +
Dempsey and colleagues
2004E3
P 65 12 7 Yes + + + + + + +
Ebrahimi and colleagues
2009E4
P 747 773 5-d washout Yes + + + + + + +
Filsoufi and colleagues
2008E5
R 72 72 6 Yes + + + + ++ + + +
Gansera and colleagues
2003E6
R 64 64 5 Not stated + + + + +
Hongo and colleagues
2002E7
P 165 59 7 No + + + + + +
Kang and colleagues
2007E8*
R 255 65 7 Not stated + + + + + +
Karabulut and colleagues
2004E9
P 1580 48 2 Yes + + + + + + +
Kim and colleagues
2008E10
R 4397 332 5 Yes + + + + + + +
Leong and colleagues
2005E11
R 834 85 7 Yes + + + + + + +
Maltais and colleagues
2008E12
P 352 101 7 Yes + + + + + + +
Mehta and colleagues
2006E13
P 2006 852 5* Yes + + + + + + +
Mengistu and colleagues
2010E14
P 50 50 <1 No + + + + + +
Nurozler and colleagues
2005E15
R 68 77 3 Yes + + + + + + +
Vaccarino and colleagues
2009E16
P 176 88 7 Yes + + + + ++ + + +
Woo and colleagues
2003E17
R 63 15 4 Not stated + + + + + +
P, Prospective study; R, retrospective study. *Some 87% of patients had clopidogrel discontinued  5 d before surgery.
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FIGURE 4. Pooled RR of immediate postoperative death in patients who received clopidogrel before CABG versus controls (observational cohort studies
only included). CI, Confidence interval.
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Dclopidogrel before surgery. Furthermore, although propen-
sity score matching is commonly used, it is frequently
used with inappropriate statistical methods.16 Indeed, we
were able to identify only 4 studies that used propensity
score matching in patients treated with clopidogrel before
CABG,7,17-19 one being a post hoc analysis of a larger
retrospective study18 (Table E2). Two studies17,19 reported
data on these propensity-matched pairs, and only the studyFIGURE 5. Pooled RR of reoperation for bleeding in patients who received cl
included). CI, Confidence interval.
672 The Journal of Thoracic and Cardiovascular Surgby Vaccarino and colleagues17 had a valid study design ac-
cording to the present meta-analysis inclusion criteria. All
these propensity-matched studies were of poor methodolog-
ical quality as assessed by Austin’s criteria16 (Table E2).
Furthermore, only one study provided data from multiple,
variable matched controls.20 Thus, any results from these
studies cannot be considered conclusive because of subop-
timal study design issues.opidogrel before CABG versus controls (observational cohort studies only
ery c March 2012
FIGURE 6. Weighted mean difference of drainage blood losses at 24 hours in patients who received clopidogrel before CABG versus controls (observa-
tional cohort studies only included). CI, Confidence interval.
Biancari et al Acquired Cardiovascular Disease
A
C
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spective, randomized studies, with all the due limitations,
provide evidence of a likely reduced risk of cardiovascular
events immediately after CABG, which is in line with the
findings after percutaneous coronary intervention. Al-
though postoperative bleeding is of great concern in these
patients, major bleeding defined by TIMI criteria was the
only parameter of severe postoperative bleeding that we
were able to evaluate from 2 prospective randomized trials,
and we did not retrieve any data on the rate of resternotomy
for bleeding. However, the TIMI criteria for major bleeding
are strict10 and may have effectively encompassed those pa-
tients who underwent resternotomy.
On the other hand, meta-analysis of a larger study popu-
lation (12,129 patients from 13 studies reporting on imme-
diate postoperative mortality) as reported in observational
studies, both prospective and retrospective, raises seriousFIGURE 7. Pooled RR of postoperative packed red blood cells transfusion in
tional cohort studies only included). CI, Confidence interval.
The Journal of Thoracic and Caconcerns regarding the safety of administration of clopidog-
rel immediately before surgical revascularization. Although
we might have expected only an increased risk of bleeding
in patients exposed to clopidogrel, we did not expect to ob-
serve a significantly increased risk of immediate postopera-
tive death associated with this drug. This finding does not
correlate with the observed reduced risk of postoperative
myocardial infarction among patients who preoperatively
received clopidogrel. However, the definition criteria of
myocardial infarction after CABG may vary markedly
from study to study, and its definition is difficult per se.
The significantly increased risk of blood transfusion and
resternotomy may explain the increased risk of death in
these patients. Indeed, need of blood transfusion is associ-
ated with a significantly increased risk of immediate and in-
termediate mortality,21,22 and a recent analysis of the
Society of Thoracic Surgeons National Cardiac Databasepatients who received clopidogrel before CABG versus controls (observa-
rdiovascular Surgery c Volume 143, Number 3 673
FIGURE 8. Pooled RR of immediate postoperativemyocardial infarction in patients who received clopidogrel before CABG versus controls (observational
cohort studies only included). CI, Confidence interval.
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Dfrom 2004 to 2007 showed a 4.5-fold higher risk of mortal-
ity in patients requiring reoperation for bleeding (9.1% vs
2.0%).23Study Limitations
This study has several limitations related to the nature of
the studies included. Because there are difficulties, ethical
and otherwise, in performing a prospective randomized
study on the preoperative use of clopidogrel in patients un-
dergoing CABG, observational studies so far have largely
failed to provide data from appropriately matched study
groups. The inclusion in the control group of patients previ-
ously exposed to clopidogrel may result in a significant bias.
This led us to exclude several large studies from this meta-
analysis, whose results are otherwise in linewith the present
findings.6,7
There were no available data on the platelet inhibitory re-
sponse to clopidogrel. Although this is certainly of major
scientific and clinical importance, any comment on this is-
sue would be speculative. A recent article did show that clo-
pidogrel responsiveness predicted blood loss and
transfusion requirement after off-pump CABG.24
These findings are not conclusive, but they do indicate
that surgeons should more actively investigate the benefits
and risks associated with preoperative use of clopidogrel
and currently available more potent antiplatelet drugs in ap-
propriate studies of better quality. Thismay allow guidelines
that extend the benefits achieved in patients undergoing per-
cutaneous coronary intervention to those requiring CABG
with improved safety and possibly reduced costs.CONCLUSIONS
The results of this study demonstrated that data on pa-
tients undergoing CABG after clopidogrel use are scanty674 The Journal of Thoracic and Cardiovascular Surgand originate from studies with suboptimal design and anal-
ysis. Despite data from randomized trials showing a trend
toward reduced cardiovascular complications, observa-
tional studies showed that patients with recent exposure to
clopidogrel have a significantly increased risk of postoper-
ative death, reoperations for bleeding, blood loss, and need
of blood transfusions.
The authors thank Steven Steinhubl for suggestions and provid-
ing supplementary data for this meta-analysis.
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1. Blasco-Colmenares E, Perl TM, Guallar E, Baumgartner
WA, Conte JV, Alejo D, et al. Aspirin plus clopidogrel and
risk of infection after coronary artery bypass surgery. Arch
Intern Med. 2009;169:788-96.
No –
2. Vaccarino GN, Thierer J, AlbertalM, VrancicM, Piccinini
F, Benzadon M, et al. Impact of preoperative clopidogrel
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13.
Yes  Propensity matching: no information
 Assessing balance between study groups: no
 Estimating the effect of treatment on the outcome: no
3. Kim JH, Newby LK, Clare RM, Shaw LK, Lodge AJ,
Smith PK, et al. Clopidogrel use and bleeding after
coronary artery bypass graft surgery. Am Heart J.
2008;156:886-92.
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4. Song SW, Youn YN, Yi G, Lee S, Yoo KJ. Effects of
continuous administration of clopidogrel before off-pump
coronary artery bypass grafting in patients with acute
coronary syndrome. Circ J. 2008;72:626-32.
Yes  Propensity matching: no information
 Assessing balance between study groups: yes
 Estimating the effect of treatment on the outcome: no
5. Ouattara A, Bouzguenda H, Le Manach Y, Leger P,
Mercadier A, Leprince P, et al. Impact of aspirin with or
without clopidogrel on postoperative bleeding and blood
transfusion in coronary surgical patients treated
prophylactically with a low-dose of aprotinin. Eur Heart
J. 2007;28:1025-32.
No –
6. Kapetanakis EI, Medlam DA, Petro KR, Haile E, Hill PC,
Dullum MK, et al. Effect of clopidogrel premedication in
off-pump cardiac surgery: are we forfeiting the benefits of
reduced hemorrhagic sequelae? Circulation.
2006;113:1667-74.
Yes
(subanalysis of study no. 7)
–
7. Kapetanakis EI, MedlamDA, Boyce SW, Haile E, Hill PC,
Dullum MK, et al. Clopidogrel administration before
coronary artery bypass grafting surgery: the cardiologist’s
panacea or the surgeon’s headache? Eur Heart J.
2005;26:576-83.
Yes  Propensity matching: no information
 Assessing balance between study groups: no
 Estimating the effect of treatment on the outcome: yes
*Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ
Cardiovasc Qual Outcomes. 2008;1:62-7.
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